Table 2 Baseline characteristics and clinical features of all included studies
References | Study type | No. of patients | Median age (months) | Male/female | Median follow-up (months) | Histology | IRS group | TNM stage | Risk group | Tumor site (favorable*/unfavorable**) | Tumor size (cm) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Ladra et al. [13] | Prospective | 57 | 42 (7.2–235) | 27/30 | 47 (14–102) | Alveolar = 16; Embryonal = 41 | Group I = 1; Group II = 7 Group III = 47; Group IV = 2 | Stage 1 = 18; Stage 2 = 14 Stage 3 = 23; Stage 4 = 2 | Low = 15; High = 0 Intermediate = 42 | Favorable = 19; Unfavorable = 38 | ≤ 5 cm (n = 36); > 5 cm (n = 21) |
Indelicato et al. [14] | Prospective | 30 | 57.6 (12–136.8) | 19/11 | 48 (6–114) | Embryonal = 30 | Group III = 30 | Stage 1 = 30 | NR | Favorable = 30; Unfavorable = 0 | 3.4 cm (range, 2.2–6.1 cm)£ 2.3 cm (range, 0.1–4.0 cm)ǂ |
Ludmir et al. [15] | Prospective | 46 | 64.8 (8.4–188.4) | 20/26 | 46.8 (12–106.8) | Alveolar = 14; Embryonal = 32 | Group I = 1; Group II = 5 Group III = 35; Group IV = 5 | Stage 1 = 20; Stage 2 = 7 Stage 3 = 14; Stage 4 = 5 | Low = 13; High = 5 Intermediate = 28 | Favorable = 21; Unfavorable = 25 | ≤ 5 cm (n = 33); > 5 cm (n = 13) |
Bradley et al. [16] | Prospective | 24 | 42 (12–243.6) | 12/12 | 11.52 (3.6–67.2) | Alveolar = 24 | Group II = 1; Group III = 23 | Stage 2 = 4; Stage 3 = 20 | NR | Favorable = 0; Unfavorable = 24 | 5.5 cm (range, 1.8–9.0 cm) |
Indelicato et al. [17] | Prospective | 31 | 31.2 (12–240) | 24/7 | 12 (12–116.4) | Alveolar = 7; Embryonal = 24 | Group III = 31 | Stage 1/2 = 24 Stage 3 = 7; Stage 4 = 0 | NR | Favorable = 0; Unfavorable = 31 | ≤ 5 cm (n = 6); > 5 cm (n = 25) |
Buszek et al. [18] | Prospective | 94 | 39.6 (1.2–187.2) | 50/44 | 48 (4.4–135.6) | Alveolar = 22; Embryonal = 71 Not specified = 1 | Group I = 6; Group II = 14 Group III = 62; Group IV = 12 | Stage 1 = 25; Stage 2 = 24 Stage 3 = 33; Stage 4 = 12 | Low = 19; High = 12 Intermediate = 63 | Favorable = 33; Unfavorable = 61 | ≤ 5 cm (n = 59); > 5 cm (n = 33) Unknown (n = 2) |
Parekh et al. [19] | Prospective | 37 | 15.6 (1.2–22.8) | 24/13 | 61.2 (8.4–26.4) | Alveolar = 12; Embryonal = 25 | Group I = 1; Group II = 3 Group III = 33; Group IV = 0 | Stage 1 = 4; Stage 2 = 5 Stage 3 = 28; Stage 4 = 0 | Low = 4; High = 0 Intermediate = 33 | Favorable = 9; Unfavorable = 28 | ≤ 5 cm (n = 13); > 5 cm (n = 24) |
Mizumoto et al. [20] | Retrospective | 55 | 60 (0–228) | 35/20 | 24.5 (1.5–320.3) | Alveolar = 18; Embryonal = 31 Others = 6 | Group I = 1; Group II = 11 Group III = 37; Group IV = 6 | NR | Low = 9; High = 7 Intermediate = 39 | Favorable = 37; Unfavorable = 18 | NR |
Suzuki et al. [21] | Retrospective | 48 | 45.6 (2.4–181.2) | 26/22 | 39.6 (4.8–141.6) | Alveolar = 22; Embryonal = 26 | NR | NR | Low = 0; High = 6 Intermediate = 42 | Favorable = 25; Unfavorable = 23 | NR |
Leiser et al. [22] | Prospective | 83 | 54 (9.6–186) | 46/37 | 44 (0.9–126.3) | Alveolar = 9; Embryonal = 74 | Group I = 2; Group II = 5 Group III = 65; Group IV = 11 | Stage 1 = 22; Stage 2 = 16 Stage 3 = 34; Stage 4 = 11 | Low = 20; High = 11 Intermediate = 52 | Favorable = 24; Unfavorable = 59 | ≤ 5 cm (n = 42); > 5 cm (n = 41) |
Weber et al. [23] | Retrospective | 39 | 69.6 (14.4–193.2) | 21/18 | 41 (9–106) | Embryonal = 38 Undifferentiated = 1 | Group I = 0; Group II = 1 Group III = 33; Group IV = 5 | Stage 1/2/3 = 34 Stage 4 = 5 | NR | Favorable = 0; Unfavorable = 39 | ≤ 5 cm (n = 11); > 5 cm(n = 28) |